We have located links that may give you full text access.
Outcomes and Costs Associated With LAMA Mono- and Combination Therapy in Patients With COPD.
Chest 2014 October 2
SESSION TITLE: COPD TreatmentSESSION TYPE: Original Investigation SlidePRESENTED ON: Sunday, October 26, 2014 at 01:30 PM - 03:00 PMPURPOSE: GOLD guidelines recommend use of long-acting muscarinic antagonist (LAMA) monotherapy as an early treatment option for patients with COPD. However, some patients initiate free combination therapy of LAMA and long-acting beta agonist (LABA) while still in the early stages of COPD. This study aims to identify treatment outcomes and costs associated with LAMA+LABA use in patients with predominantly low to moderate complexity COPD, as defined by a claims based algorithm.METHODS: Patients initiating LAMA alone or LAMA+LABA were identified in the MarketScan database (1/1/09-3/31/12). Included patients were >40 years, had medical and pharmacy claims data for 12 months before and after index date, had ≥1 claim for COPD (ICD-9 491, 492, 496), no claims for asthma, non-specified bronchitis, respiratory cancer or cystic fibrosis ≤1 year, and no LABA or LAMA use ≤1 year. Patients taking LAMA+LABA were identified first due to limited sample size. LAMA patients were randomly selected using the same criteria in a 5:1 ratio. Demographic and clinical characteristics were compared between groups using chi-square and t-tests. Logistic regression models were used to adjust for baseline variability and assess differences in the likelihood of utilization between groups. Multivariate generalized linear regression models were used to compare all-cause and COPD-related healthcare costs.RESULTS: Inclusion criteria identified 274 LAMA+LABA patients; 1,370 LAMA monotherapy patients were then randomly selected. Patients in both groups were similar in terms of age, geographic region, and disease complexity, while patients on LAMA+LABA had more comorbidities. Adjusting for observed differences in baseline characteristics, LAMA+LABA patients had greater all-cause healthcare resource utilization and associated costs; however, only drug costs were significantly different, with higher costs for patients on LAMA+LABA compared with patients on LAMA alone ($7,902 vs $5,808, p<0.0001). Results were similar for COPD-related healthcare resource utilization.CONCLUSIONS: COPD patients taking LAMA+LABA therapy had similar healthcare resource utilization and costs when compared to patients taking LAMA alone, despite controlling for baseline characteristics like disease complexity and comorbidities.CLINICAL IMPLICATIONS: The addition of LABA to LAMA therapy in low or moderate complexity COPD patients may result in higher drug costs with no significant reduction in all-cause and COPD-related healthcare resource utilization.DISCLOSURE: Michelle Mocarski: Employee: Forest Research Institute Wenyi Wang: Consultant fee, speaker bureau, advisory committee, etc.: Forest Research Institute Shawn Sun: Employee: Forest Research Institute Mona Khalid: Consultant fee, speaker bureau, advisory committee, etc.: Forest Research Institute Ronald Aubert: Consultant fee, speaker bureau, advisory committee, etc.: Forest Research Institute Shailja Dixit: Employee: Forest Research InstituteNo Product/Research Disclosure Information.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app